Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) EVP Sells 6,000 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $232.37, for a total value of $1,394,220.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares of the company's stock, valued at $8,530,302.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Up 1.2 %

NASDAQ:UTHR traded up $2.73 on Thursday, hitting $233.93. The stock had a trading volume of 521,665 shares, compared to its average volume of 429,655. The company has a market cap of $11.01 billion, a PE ratio of 11.79 and a beta of 0.52. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $261.54. The business's fifty day moving average is $227.00 and its 200 day moving average is $227.69. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. During the same quarter last year, the firm posted $2.67 EPS. United Therapeutics's revenue was up 25.1% compared to the same quarter last year. On average, equities research analysts expect that United Therapeutics Co. will post 23.46 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. GAMMA Investing LLC bought a new stake in United Therapeutics during the 4th quarter worth approximately $43,000. Neo Ivy Capital Management purchased a new position in United Therapeutics during the 2nd quarter worth $48,000. Atlas Capital Advisors LLC bought a new stake in shares of United Therapeutics in the 4th quarter worth $51,000. Northwestern Mutual Wealth Management Co. raised its holdings in shares of United Therapeutics by 49.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 65 shares during the last quarter. Finally, Zions Bancorporation N.A. bought a new position in shares of United Therapeutics during the first quarter valued at about $66,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Analysts Set New Price Targets

UTHR has been the subject of several analyst reports. The Goldman Sachs Group raised shares of United Therapeutics from a "sell" rating to a "neutral" rating and raised their price target for the company from $213.00 to $215.00 in a research note on Monday, February 12th. Wedbush reiterated an "outperform" rating and issued a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. Wells Fargo & Company raised their price objective on United Therapeutics from $309.00 to $325.00 and gave the stock an "overweight" rating in a research report on Thursday, March 7th. HC Wainwright reiterated a "buy" rating and issued a $300.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, Leerink Partnrs restated an "outperform" rating on shares of United Therapeutics in a report on Monday, February 5th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $294.40.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.